Targeted approaches to induce immune tolerance for Pompe disease therapy

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 15053-

  Doerfler, Phillip A ^a   Nayak, Sushrusha ^b   Corti, Manuela ^a   Morel, Laurence ^a   Herzog, Roland W ^a   Byrne, Barry J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSIDASE; CHAPERONE; GLUCAN 1,4 ALPHA GLUCOSIDASE; IMMUNOMODULATING AGENT; LYMPHOCYTE ANTIGEN;

ANTIGEN SPECIFICITY; ENZYME REPLACEMENT; GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SAFETY; ALLERGIC REACTION; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SAFETY; IMMUNOMODULATION;

EID: 85007398218     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.53     Document Type: Review

References (160)

1. 1 Brooks, DA, Kakavanos, R, Hopwood, JJ, Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 9 (2003), 450–453.
2. 2 Ponder, KP, Immune response hinders therapy for lysosomal storage diseases. J Clin Invest 118 (2008), 2686–2689.
3. 3 Markusic, DM, Herzog, RW, Liver-directed adeno-associated viral gene therapy for hemophilia. J Genet Syndr Gene Ther 1 (2012), 1–9.
4. 4 Mays, LE, Wilson, JM, The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 19 (2011), 16–27.
5. 5 Rogers, GL, Martino, AT, Aslanidi, GV, Jayandharan, GR, Srivastava, A, Herzog, RW, Innate immune responses to AAV vectors. Front Microbiol, 2, 2011, 194.
6. 6 Mingozzi, F, High, KA, Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
7. 7 Basner-Tschakarjan, E, Bijjiga, E, Martino, AT, Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors. Front Immunol, 5, 2014, 28.
8. 8 Banting, FG, Best, CH, Collip, JB, Campbell, WR, Fletcher, AA, Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12 (1922), 141–146.
9. 9 Meikle, PJ, Hopwood, JJ, Clague, AE, Carey, WF, Prevalence of lysosomal storage disorders. JAMA 281 (1999), 249–254.
10. 10 Boustany, RM, Lysosomal storage diseases–the horizon expands. Nat Rev Neurol 9 (2013), 583–598.
11. 11 Kishnani, PS, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68 (2007), 99–109.
12. 12 Byrne, BJ, Kishnani, PS, Case, LE, Merlini, L, Müller-Felber, W, Prasad, S, et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 103 (2011), 1–11.
13. 13 van der Ploeg, AT, Reuser, AJ, Pompe's disease. Lancet 372 (2008), 1342–1353.
14. 14 DeRuisseau, LR, Fuller, DD, Qiu, K, DeRuisseau, KC, Donnelly, WH Jr, Mah, C, et al. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci USA 106 (2009), 9419–9424.
15. 15 Falk, DJ, Todd, AG, Lee, S, Soustek, MS, ElMallah, MK, Fuller, DD, et al. Peripheral nerve and neuromuscular junction pathology in Pompe disease. Hum Mol Genet 24 (2015), 625–636.
16. 16 Tripathi, SP, Phadke, MS, Kerkar, PG, Giant heart of classical infantile-onset Pompe disease with mirror image dextrocardia. Circ Cardiovasc Imaging, 8, 2015, e003637.
17. 17 Lee, KZ, Qiu, K, Sandhu, MS, Elmallah, MK, Falk, DJ, Lane, MA, et al. Hypoglossal neuropathology and respiratory activity in pompe mice. Front Physiol, 2, 2011, 31.
18. 18 Kishnani, PS, Hwu, WL, Mandel, H, Nicolino, M, Yong, F, Corzo, D, Infantile-Onset Pompe Disease Natural History Study Group, A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148 (2006), 671–676.
19. 19 Moreland, RJ, Jin, X, Zhang, XK, Decker, RW, Albee, KL, Lee, KL, et al. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem 280 (2005), 6780–6791.
20. 20 Ghosh, P, Dahms, NM, Kornfeld, S, Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4 (2003), 202–212.
21. 21 Koeberl, DD, Luo, X, Sun, B, McVie-Wylie, A, Dai, J, Li, S, et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab 103 (2011), 107–112.
22. 22 Farah, BL, Madden, L, Li, S, Nance, S, Bird, A, Bursac, N, et al. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease. FASEB J 28 (2014), 2272–2280.
23. 23 Koeberl, DD, Li, S, Dai, J, Thurberg, BL, Bali, D, Kishnani, PS, β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 105 (2012), 221–227.
24. 24 Koeberl, DD, Kishnani, PS, Chen, YT, Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis 30 (2007), 159–164.
25. 25 Mogilnicka, E, Nielsen, M, Repeated treatment with clenbuterol produces desensitization of rat brain beta- and alpha 2-adrenoceptors without changes of alpha 1-adrenoceptors. Eur J Pharmacol 121 (1986), 107–111.
26. 26 Cardone, M, Porto, C, Tarallo, A, Vicinanza, M, Rossi, B, Polishchuk, E, et al. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics, 1, 2008, 6.
27. 27 Mah, CS, Soustek, MS, Todd, AG, McCall, A, Smith, BK, Corti, M, et al. Adeno-associated virus-mediated gene therapy for metabolic myopathy. Hum Gene Ther 24 (2013), 928–936.
28. 28 Byrne, BJ, Falk, DJ, Clément, N, Mah, CS, Gene therapy approaches for lysosomal storage disease: next-generation treatment. Hum Gene Ther 23 (2012), 808–815.
29. 29 Wagemaker, G, Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders. Hum Gene Ther 25 (2014), 862–865.
30. 30 Mah, C, Cresawn, KO, Fraites, TJ Jr, Pacak, CA, Lewis, MA, Zolotukhin, I, et al. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 12 (2005), 1405–1409.
31. 31 Mah, CS, Falk, DJ, Germain, SA, Kelley, JS, Lewis, MA, Cloutier, DA, et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 18 (2010), 502–510.
32. 32 Rucker, M, Fraites, TJ Jr, Porvasnik, SL, Lewis, MA, Zolotukhin, I, Cloutier, DA, et al. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development 131 (2004), 3007–3019.
33. 33 Elmallah, MK, Falk, DJ, Nayak, S, Federico, RA, Sandhu, MS, Poirier, A, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther 22 (2014), 702–712.
34. 34 Fraites, TJ Jr, Schleissing, MR, Shanely, RA, Walter, GA, Cloutier, DA, Zolotukhin, I, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 5 (2002), 571–578.
35. 35 Qiu, K, Falk, DJ, Reier, PJ, Byrne, BJ, Fuller, DD, Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther 20 (2012), 21–27.
36. 36 Cresawn, KO, Fraites, TJ, Wasserfall, C, Atkinson, M, Lewis, M, Porvasnik, S, et al. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. Hum Gene Ther 16 (2005), 68–80.
37. 37 Ziegler, RJ, Bercury, SD, Fidler, J, Zhao, MA, Foley, J, Taksir, TV, et al. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 19 (2008), 609–621.
38. 38 Sun, B, Zhang, H, Franco, LM, Young, SP, Schneider, A, Bird, A, et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 11 (2005), 57–65.
39. 39 Wang, G, Young, SP, Bali, D, Hutt, J, Li, S, Benson, J, et al. Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. Mol Ther Methods Clin Dev, 1, 2014, 14018.
40. 40 Todd, AG, McElroy, JA, Grange, RW, Fuller, DD, Walter, GA, Byrne, BJ, et al. Correcting neuromuscular deficits with gene therapy in Pompe disease. Ann Neurol 78 (2015), 222–234.
41. 41 Falk, DJ, Mah, CS, Soustek, MS, Lee, KZ, Elmallah, MK, Cloutier, DA, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther 21 (2013), 1661–1667.
42. 42 ElMallah, MK, Falk, DJ, Lane, MA, Conlon, TJ, Lee, KZ, Shafi, NI, et al. Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 23 (2012), 148–156.
43. 43 Falk, DJ, Soustek, MS, Todd, AG, Mah, CS, Cloutier, DA, Kelley, JS, et al. Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol Ther Methods Clin Dev, 2, 2015, 15007.
44. 44 Schuster, DJ, Dykstra, JA, Riedl, MS, Kitto, KF, Belur, LR, McIvor, RS, et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat, 8, 2014, 42.
45. 45 Smith, BK, Collins, SW, Conlon, TJ, Mah, CS, Lawson, LA, Martin, AD, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther 24 (2013), 630–640.
46. 46 Byrne, PI, Collins, S, Mah, CC, Smith, B, Conlon, T, Martin, SD, et al. Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev 25 (2014), 134–163.
47. 47 Conlon, TJ, Erger, K, Porvasnik, S, Cossette, T, Roberts, C, Combee, L, et al. Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid α-glucosidase. Hum Gene Ther Clin Dev 24 (2013), 127–133.
48. 48 Richard, E, Douillard-Guilloux, G, Batista, L, Caillaud, C, Correction of glycogenosis type 2 by muscle-specific lentiviral vector. In Vitro Cell Dev Biol Anim 44 (2008), 397–406.
49. 49 Sato, Y, Kobayashi, H, Higuchi, T, Shimada, Y, Era, T, Kimura, S, et al. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol Ther Methods Clin Dev, 2, 2015, 15023.
50. 50 Kyosen, SO, Iizuka, S, Kobayashi, H, Kimura, T, Fukuda, T, Shen, J, et al. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther 17 (2010), 521–530.
51. 51 van Til, NP, Stok, M, Aerts Kaya, FS, de Waard, MC, Farahbakhshian, E, Visser, TP, et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood 115 (2010), 5329–5337.
52. 52 Douillard-Guilloux, G, Richard, E, Batista, L, Caillaud, C, Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease. J Gene Med 11 (2009), 279–287.
53. 53 Zufferey, R, Dull, T, Mandel, RJ, Bukovsky, A, Quiroz, D, Naldini, L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72 (1998), 9873–9880.
54. 54 Schambach, A, Zychlinski, D, Ehrnstroem, B, Baum, C, Biosafety features of lentiviral vectors. Hum Gene Ther 24 (2013), 132–142.
55. 55 Worsham, DN, Schuesler, T, von Kalle, C, Pan, D, In vivo gene transfer into adult stem cells in unconditioned mice by in situ delivery of a lentiviral vector. Mol Ther 14 (2006), 514–524.
56. 56 Lévy, C, Amirache, F, Costa, C, Frecha, C, Muller, CP, Kweder, H, et al. Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells. Mol Ther 20 (2012), 1699–1712.
57. 57 Espana-Agusti, J, Tuveson, DA, Adams, DJ, Matakidou, A, A minimally invasive, lentiviral based method for the rapid and sustained genetic manipulation of renal tubules. Sci Rep, 5, 2015, 11061.
58. 58 Yan, Z, Stewart, ZA, Sinn, PL, Olsen, JC, Hu, J, McCray, PB Jr, et al. Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy. Hum Gene Ther Clin Dev 26 (2015), 38–49.
59. 59 Cesana, D, Sgualdino, J, Rudilosso, L, Merella, S, Naldini, L, Montini, E, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 122 (2012), 1667–1676.
60. 60 Mátrai, J, Chuah, MK, VandenDriessche, T, Recent advances in lentiviral vector development and applications. Mol Ther 18 (2010), 477–490.
61. 61 Carbonaro Sarracino, D, Tarantal, AF, Lee, CC, Martinez, M, Jin, X, Wang, X, et al. Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys. Mol Ther 22 (2014), 1803–1816.
62. 62 Aiuti, A, Biasco, L, Scaramuzza, S, Ferrua, F, Cicalese, MP, Baricordi, C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 2013, 1233151.
63. 63 Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 2013, 1233158.
64. 64 Naphade, S, Sharma, J, Gaide Chevronnay, HP, Shook, MA, Yeagy, BA, Rocca, CJ, et al. Brief reports: lysosomal cross-correction by hematopoietic stem cell-derived macrophages via tunneling nanotubes. Stem Cells 33 (2015), 301–309.
65. 65 Brooks, DA, Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab 68 (1999), 268–275.
66. 66 Bigger, BW, Saif, M, Linthorst, GE, The role of antibodies in enzyme treatments and therapeutic strategies. Best Pract Res Clin Endocrinol Metab 29 (2015), 183–194.
67. 67 van Gelder, CM, Hoogeveen-Westerveld, M, Kroos, MA, Plug, I, van der Ploeg, AT, Reuser, AJ, Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis 38 (2015), 305–314.
68. 68 Kishnani, PS, Goldenberg, PC, DeArmey, SL, Heller, J, Benjamin, D, Young, S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99 (2010), 26–33.
69. 69 Harmatz, P, Enzyme replacement therapies and immunogenicity in lysosomal storage diseases: is there a pattern?. Clin Ther 37 (2015), 2130–2134.
70. 70 Kroos, M, Pomponio, RJ, van Vliet, L, Palmer, RE, Phipps, M, Van der Helm, R, et al., GAA Database Consortium, Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 29 (2008), E13–E26.
71. 71 Basner-Tschakarjan, E, Mingozzi, F, Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol, 5, 2014, 350.
72. 72 Nayak, S, Sivakumar, R, Cao, O, Daniell, H, Byrne, BJ, Herzog, RW, Mapping the T helper cell response to acid α-glucosidase in Pompe mice. Mol Genet Metab 106 (2012), 189–195.
73. 73 de Vries, JM, van der Beek, NA, Kroos, MA, Ozkan, L, van Doorn, PA, Richards, SM, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101 (2010), 338–345.
74. 74 Zhang, P, Luo, X, Bird, A, Li, S, Koeberl, DD, Deficiency in MyD88 signaling results in decreased antibody responses to an adeno-associated virus vector in murine Pompe disease. Biores Open Access 1 (2012), 109–114.
75. 75 Bronsema, KJ, Bischoff, R, Pijnappel, WW, van der Ploeg, AT, van de Merbel, NC, Absolute quantification of the total and antidrug antibody-bound concentrations of recombinant human α-glucosidase in human plasma using protein G extraction and LC-MS/MS. Anal Chem 87 (2015), 4394–4401.
76. 76 Nayak, S, Doerfler, PA, Porvasnik, SL, Cloutier, DD, Khanna, R, Valenzano, KJ, et al. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS One, 9, 2014, e98336.
77. 77 Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
78. 78 Patel, TT, Banugaria, SG, Case, LE, Wenninger, S, Schoser, B, Kishnani, PS, The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab 106 (2012), 301–309.
79. 79 Bali, DS, Goldstein, JL, Banugaria, S, Dai, J, Mackey, J, Rehder, C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet 160C (2012), 40–49.
80. 80 Lacaná, E, Yao, LP, Pariser, AR, Rosenberg, AS, The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C Semin Med Genet 160C (2012), 30–39.
81. 81 Sack, BK, Herzog, RW, Terhorst, C, Markusic, DM, Development of gene transfer for induction of antigen-specific tolerance. Mol Ther Methods Clin Dev, 1, 2014, 14013.
82. 82 LeBowitz, JH, Grubb, JH, Maga, JA, Schmiel, DH, Vogler, C, Sly, WS, Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci USA 101 (2004), 3083–3088.
83. 83 Maga, JA, Zhou, J, Kambampati, R, Peng, S, Wang, X, Bohnsack, RN, et al. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice. J Biol Chem 288 (2013), 1428–1438.
84. 84 Kan, SH, Aoyagi-Scharber, M, Le, SQ, Vincelette, J, Ohmi, K, Bullens, S, et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proc Natl Acad Sci USA 111 (2014), 14870–14875.
85. 85 Kishnani, PS, Nicolino, M, Voit, T, Rogers, RC, Tsai, AC, Waterson, J, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149 (2006), 89–97.
86. 86 Byrne, B, Barohn, R, Barshop, B, Bratkovic, D, Desnuelle, C, Geberhiwot, T, et al. POM-001 phase 1/2 study of BMN 701, GILT-tagged recombinant human (rh) GAA in late-onset Pompe disease: initial experience in 22 patients. Mol Genet Metab, 108, 2013, S28.
87. 87 Parenti, G, Zuppaldi, A, Gabriela Pittis, M, Rosaria Tuzzi, M, Annunziata, I, Meroni, G, et al. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther 15 (2007), 508–514.
88. 88 Flanagan, JJ, Rossi, B, Tang, K, Wu, X, Mascioli, K, Donaudy, F, et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat 30 (2009), 1683–1692.
89. 89 Porto, C, Cardone, M, Fontana, F, Rossi, B, Tuzzi, MR, Tarallo, A, et al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 17 (2009), 964–971.
90. 90 Khanna, R, Flanagan, JJ, Feng, J, Soska, R, Frascella, M, Pellegrino, LJ, et al. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One, 7, 2012, e40776.
91. 91 Khanna, R, Powe, AC Jr, Lun, Y, Soska, R, Feng, J, Dhulipala, R, et al. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease. PLoS One, 9, 2014, e102092.
92. 92 Parenti, G, Fecarotta, S, la Marca, G, Rossi, B, Ascione, S, Donati, MA, et al. A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther 22 (2014), 2004–2012.
93. 93 Porto, C, Ferrara, MC, Meli, M, Acampora, E, Avolio, V, Rosa, M, et al. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther 20 (2012), 2201–2211.
94. 94 Doerfler, PA, Kelley, JS, Nayak, S, Lawson, LA, Byrne, BJ, Pharmacological chaperones prevent the precipitation of rhGAA by anti-GAA antibodies during enzyme replacement therapy. Mol Genet Metab, 111, 2014, S38.
95. 95 Wang, J, Lozier, J, Johnson, G, Kirshner, S, Verthelyi, D, Pariser, A, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 26 (2008), 901–908.
96. 96 Mendelsohn, NJ, Messinger, YH, Rosenberg, AS, Kishnani, PS, Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 360 (2009), 194–195.
97. 97 Banugaria, SG, Patel, TT, Mackey, J, Das, S, Amalfitano, A, Rosenberg, AS, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab 105 (2012), 677–680.
98. 98 Joly, MS, Martin, RP, Mitra-Kaushik, S, Phillips, L, D'Angona, A, Richards, SM, et al. Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa. J Immunol 193 (2014), 3947–3958.
99. 99 Genestier, L, Paillot, R, Fournel, S, Ferraro, C, Miossec, P, Revillard, JP, Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102 (1998), 322–328.
100. 100 Markic, J, Polic, B, Kuzmanic-Samija, R, Marusic, E, Stricevic, L, Metlicic, V, et al. Immune modulation therapy in a CRIM-positive and IgG antibody-positive infant with Pompe disease treated with alglucosidase alfa: a case report. JIMD Rep 2 (2012), 11–15.
101. 101 Vincent, FB, Saulep-Easton, D, Figgett, WA, Fairfax, KA, Mackay, F, The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24 (2013), 203–215.
102. 102 Doerfler, PA, Nayak, S, Herzog, RW, Morel, L, Byrne, BJ, BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clin Immunol 158 (2015), 140–147.
103. 103 Scholz, JL, Crowley, JE, Tomayko, MM, Steinel, N, O'Neill, PJ, Quinn, WJ 3rd, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 105 (2008), 15517–15522.
104. 104 Elder, ME, Nayak, S, Collins, SW, Lawson, LA, Kelley, JS, Herzog, RW, et al. B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 163 (2013), 847–854.
105. 105 Gerriets, VA, Rathmell, JC, Metabolic pathways in T cell fate and function. Trends Immunol 33 (2012), 168–173.
106. 106 Limon, JJ, Fruman, DA, Akt and mTOR in B cell activation and differentiation. Front Immunol, 3, 2012, 228.
107. 107 Moghimi, B, Sack, BK, Nayak, S, Markusic, DM, Mah, CS, Herzog, RW, Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 9 (2011), 1524–1533.
108. 108 Nayak, S, Cao, O, Hoffman, BE, Cooper, M, Zhou, S, Atkinson, MA, et al. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J Thromb Haemost 7 (2009), 1523–1532.
109. 109 Sarkar, D, Biswas, M, Liao, G, Seay, HR, Perrin, GQ, Markusic, DM, et al. Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia. Mol Ther Methods Clin Dev, 1, 2014, 14030.
110. 110 Biswas, M, Sarkar, D, Kumar, SR, Nayak, S, Rogers, GL, Markusic, DM, et al. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood 125 (2015), 2937–2947.
111. 111 Battaglia, M, Stabilini, A, Roncarolo, MG, Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105 (2005), 4743–4748.
112. 112 Kuhns, MS, Davis, MM, Garcia, KC, Deconstructing the form and function of the TCR/CD3 complex. Immunity 24 (2006), 133–139.
113. 113 Ohashi, T, Iizuka, S, Shimada, Y, Higuchi, T, Eto, Y, Ida, H, et al. Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice. Mol Ther 20 (2012), 1924–1931.
114. 114 Sun, B, Banugaria, SG, Prater, SN, Patel, TT, Fredrickson, K, Ringler, DJ, et al. Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Mol Genet Metab Reports 1 (2014), 446–450.
115. 115 Banugaria, SG, Prater, SN, McGann, JK, Feldman, JD, Tannenbaum, JA, Bailey, C, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 15 (2013), 123–131.
116. 116 Shapiro-Shelef, M, Calame, K, Regulation of plasma-cell development. Nat Rev Immunol 5 (2005), 230–242.
117. 117 Lin, W, Seshasayee, D, Lee, WP, Caplazi, P, McVay, S, Suto, E, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheumatol 67 (2015), 215–224.
118. 118 Markusic, DM, Hoffman, BE, Perrin, GQ, Nayak, S, Wang, X, LoDuca, PA, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 5 (2013), 1698–1709.
119. 119 Han, SO, Li, S, Brooks, ED, Masat, E, Leborgne, C, Banugaria, S, et al. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum Gene Ther 26 (2015), 26–35.
120. 120 Corti, M, Elder, M, Falk, D, Lawson, L, Smith, B, Nayak, S, et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev, 1, 2014, 14033.
121. 121 Corti, M, Cleaver, B, Clément, N, Conlon, TJ, Faris, KJ, Wang, G, et al. Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev 26 (2015), 185–193.
122. 122 Jacobson, SG, Cideciyan, AV, Roman, AJ, Sumaroka, A, Schwartz, SB, Heon, E, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 372 (2015), 1920–1926.
123. 123 Schmidt, A, Oberle, N, Krammer, PH, Molecular mechanisms of treg-mediated T cell suppression. Front Immunol, 3, 2012, 51.
124. 124 Palomares, O, Martín-Fontecha, M, Lauener, R, Traidl-Hoffmann, C, Cavkaytar, O, Akdis, M, et al. Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β. Genes Immun 15 (2014), 511–520.
125. 125 Liao, G, O'Keeffe, MS, Wang, G, van Driel, B, de Waal Malefyt, R, Reinecker, HC, et al. Glucocorticoid-induced TNF receptor family-related protein ligand is requisite for optimal functioning of regulatory CD4(+) T cells. Front Immunol, 5, 2014, 35.
126. 126 Cao, O, Dobrzynski, E, Wang, L, Nayak, S, Mingle, B, Terhorst, C, et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110 (2007), 1132–1140.
127. 127 Nayak, S, Sarkar, D, Perrin, GQ, Moghimi, B, Hoffman, BE, Zhou, S, et al. Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B. Front Microbiol, 2, 2011, 244.
128. 128 Wang, X, Sherman, A, Liao, G, Leong, KW, Daniell, H, Terhorst, C, et al. Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev 65 (2013), 759–773.
129. 129 Ohashi, T, Iizuka, S, Shimada, Y, Eto, Y, Ida, H, Hachimura, S, et al. Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse. Mol Genet Metab 103 (2011), 98–100.
130. 130 Su, J, Sherman, A, Doerfler, PA, Byrne, BJ, Herzog, RW, Daniell, H, Oral delivery of acid alpha glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnol J 13 (2015), 1023–1032.
131. 131 Wang, X, Su, J, Sherman, A, Rogers, GL, Liao, G, Hoffman, BE, et al. Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood 125 (2015), 2418–2427.
132. 132 Kwon, KC, Daniell, H, Low-cost oral delivery of protein drugs bioencapsulated in plant cells. Plant Biotechnol J 13 (2015), 1017–1022.
133. 133 Cremel, M, Guerin, N, Campello, G, Barthe, Q, Berlier, W, Horand, F, et al. Innovative approach in Pompe disease therapy: induction of immune tolerance by antigen-encapsulated red blood cells. Int J Pharm 491 (2015), 69–77.
134. 134 Cremel, M, Guérin, N, Horand, F, Banz, A, Godfrin, Y, Red blood cells as innovative antigen carrier to induce specific immune tolerance. Int J Pharm 443 (2013), 39–49.
135. 135 St-Pierre, C, Trofimov, A, Brochu, S, Lemieux, S, Perreault, C, Differential features of AIRE-induced and AIRE-independent promiscuous gene expression in thymic epithelial cells. J Immunol 195 (2015), 498–506.
136. 136 Kisand, K, Peterson, P, Laan, M, Lymphopenia-induced proliferation in aire-deficient mice helps to explain their autoimmunity and differences from human patients. Front Immunol, 5, 2014, 51.
137. 137 Chuprin, A, Avin, A, Goldfarb, Y, Herzig, Y, Levi, B, Jacob, A, et al. The deacetylase Sirt1 is an essential regulator of Aire-mediated induction of central immunological tolerance. Nat Immunol 16 (2015), 737–745.
138. 138 Wilkinson, FL, Sergijenko, A, Langford-Smith, KJ, Malinowska, M, Wynn, RF, Bigger, BW, Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation. Mol Ther 21 (2013), 868–876.
139. 139 Tarantal, AF, Giannoni, F, Lee, CC, Wherley, J, Sumiyoshi, T, Martinez, M, et al. Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys. Mol Ther 20 (2012), 1033–1045.
140. 140 Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467 (2010), 318–322.
141. 141 Chu, Q, Moreland, RJ, Gao, L, Taylor, KM, Meyers, E, Cheng, SH, et al. Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery. Mol Ther 18 (2010), 2146–2154.
142. 142 Crispe, IN, The liver as a lymphoid organ. Annu Rev Immunol 27 (2009), 147–163.
143. 143 Crispe, IN, Hepatic T cells and liver tolerance. Nat Rev Immunol 3 (2003), 51–62.
144. 144 Breous, E, Somanathan, S, Vandenberghe, LH, Wilson, JM, Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 50 (2009), 612–621.
145. 145 Burghardt, S, Erhardt, A, Claass, B, Huber, S, Adler, G, Jacobs, T, et al. Hepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells. J Immunol 191 (2013), 5574–5582.
146. 146 Bailis, W, Yashiro-Ohtani, Y, Fang, TC, Hatton, RD, Weaver, CT, Artis, D, et al. Notch simultaneously orchestrates multiple helper T cell programs independently of cytokine signals. Immunity 39 (2013), 148–159.
147. 147 Vahl, JC, Drees, C, Heger, K, Heink, S, Fischer, JC, Nedjic, J, et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool. Immunity 41 (2014), 722–736.
148. 148 Franco, LM, Sun, B, Yang, X, Bird, A, Zhang, H, Schneider, A, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12 (2005), 876–884.
149. 149 Sun, B, Bird, A, Young, SP, Kishnani, PS, Chen, YT, Koeberl, DD, Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 81 (2007), 1042–1049.
150. 150 Sun, B, Kulis, MD, Young, SP, Hobeika, AC, Li, S, Bird, A, et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 18 (2010), 353–360.
151. 151 Zhang, P, Sun, B, Osada, T, Rodriguiz, R, Yang, XY, Luo, X, et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther 23 (2012), 460–472.
152. 152 Vandendriessche, T, Thorrez, L, Acosta-Sanchez, A, Petrus, I, Wang, L, Ma, L, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 5 (2007), 16–24.
153. 153 Zincarelli, C, Soltys, S, Rengo, G, Rabinowitz, JE, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16 (2008), 1073–1080.
154. 154 Marsic, D, Govindasamy, L, Currlin, S, Markusic, DM, Tseng, YS, Herzog, RW, et al. Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol Ther 22 (2014), 1900–1909.
155. 155 Shen, S, Horowitz, ED, Troupes, AN, Brown, SM, Pulicherla, N, Samulski, RJ, et al. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J Biol Chem 288 (2013), 28814–28823.
156. 156 Li, C, Diprimio, N, Bowles, DE, Hirsch, ML, Monahan, PE, Asokan, A, et al. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol 86 (2012), 7752–7759.
157. 157 Carson, KR, Focosi, D, Major, EO, Petrini, M, Richey, EA, West, DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10 (2009), 816–824.
158. 158 Du Toit, G, Roberts, G, Sayre, PH, Bahnson, HT, Radulovic, S, Santos, AF, et al., LEAP Study Team, Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 372 (2015), 803–813.
159. 159 Sherman, A, Su, J, Lin, S, Wang, X, Herzog, RW, Daniell, H, Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood 124 (2014), 1659–1668.
160. 160 Su, J, Zhu, L, Sherman, A, Wang, X, Lin, S, Kamesh, A, et al. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials 70 (2015), 84–93.